Study: Cancer patients may not be at higher risk from COVID
From the start of the coronavirus pandemic, cancer patients have been deemed a high-risk group for COVID, despite the lack ...
Israel Hayom is a media organization founded on the belief that the Israeli public deserves better journalism—more balanced, more accurate, and more reliable. Journalism that speaks rather than shouts. Journalism that is trustworthy, objective, and matter-of-fact. A different kind of journalism, offered free of charge. The first print edition was published on July 30, 2007, and in 2010 Israel Hayom became the Israeli newspaper with the highest weekday readership. The newspaper’s publisher is Dr. Miriam Adelson. Its Editor-in-Chief is Omar Lachmanovitch, and its founding editor is Amos Regev. Israel Hayom’s Hebrew and English websites, as well as its Android and iOS applications, provide around-the-clock news coverage, exclusive content, breaking news and updates, analysis and commentary, video, podcasts, and live broadcasts. The digital platforms of Israel Hayom include news and opinion channels covering culture and entertainment, lifestyle, technology, sports, business and consumer affairs, health, military affairs, food, Judaism, tourism, and automobiles. In 2021, a new Hebrew-language website and mobile application were launched to provide users with a fast, up-to-date, secure, and convenient experience. The content of the newspaper’s print edition is also available online through a daily digital edition and can be received via newsletter. “The Israel Hayom Clique,” the publication’s exclusive benefits club, offers website users discounts and special promotions on products and services. Israel Hayom welcomes feedback, criticism, and suggestions for improvement from its readers. You can contact the organization by email at hayom@israelhayom.co.il
From the start of the coronavirus pandemic, cancer patients have been deemed a high-risk group for COVID, despite the lack ...
Investors seem to think so: Israeli biotech startup BioProtect has raised $25 million in a Series D financing round.
Coronavirus testing continues in order to help authorities cut off outbreaks. Tests for urgent surgeries, women in labor, and cancer ...
Fundraising round will support company's first clinical trial of non-thermal plasma technology, which directly targets and kills cancer cells and ...
Alpha Tau says it has successfully completed its first-in-human clinical trial of Alpha DaRT, a radiation cancer therapy, with squamous ...
The company's treatment uses special needles to inject liquid nitrogen to freeze and destroy tumors without the need for surgery.
Due to the harsh terms of his parole, former American-Israeli spy Jonathan Pollard cannot adequately care for his wife, Esther, ...
Former vice president and Democratic presidential hopeful lost his son in 2015 to brain cancer. At a campaign event in ...
A groundbreaking study at Israel’s Sheba Medical Center tests efficacy of a new treatment based on medication that attacks a ...
The first issue of Israel Hayom appeared on July 30, 2007. Israel Hayom was founded on the belief that the Israeli public deserves better, more balanced and more accurate journalism. Journalism that speaks, not shouts. Journalism of a different kind. And free of charge.
All rights reserved to Israel Hayom
Hosted by sPD.co.il
[contact-form-7 id=”508379″ html_id=”isrh_form_Newsletter_en” title=”newsletter_subscribe”]